Samy Goldfarb

Recent Posts

Boston Therapeutics Strengthens its Medical Advisory Board

Posted by Samy Goldfarb

September 24, 2014 at 9:55 AM

Boston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Meng Hee Tan, M.D. to serve as its Consulting Medical Director and a member of its Medical Advisory Team. Dr. Tan is expected to help guide the Company's development of its diabetes-related treatments.

Read More

Topics: BTHE

Boston Therapeutics Signs Agreement for Phase III Study of BTI-320

Posted by Samy Goldfarb

September 22, 2014 at 3:41 PM

Boston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes, announced that it signed a clinical trial agreement with the prestigious Joslin Diabetes Center in Boston to be the lead clinic for the Company’s Phase III study of its candidate BTI-320.

BTI-320, a new generation of alpha glucosidase inhibitor, is a non-systemic chewable tablet designed to reduce post-meal elevation of blood glucose. BTI-320 is designed to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

Read More

Topics: BTHE

Boston Therapeutics $BTHE Announces Strategic Marketing Agreement for SUGARDOWN®

Posted by Samy Goldfarb

May 20, 2014 at 12:05 PM

http://www.sugardown.com/

Boston Therapeutics (BTHE-OTC), a developer of compounds that address blood sugar management and inflammatory disease, has announced the signing of a strategic marketing agreement with Benchworks SD, LLC, a branding and marketing agency, aimed at increasing brand awareness and sales of SUGARDOWN®.
 
SUGARDOWN is Boston Therapeutics’ currently marketed dietary supplement that, when taken prior to meals, supports a reduction in the post-meal elevation in glucose resulting in healthy blood sugar levels. Clinical studies conducted at the University of Sydney in Australia indicated that the consumption of SUGARDOWN prior to a high carbohydrate meal of rice resulted in lower incremental area under the curve (iAUC) measurements for glucose and insulin, indicating a reduction in post-meal elevation of blood glucose and insulin when compared with the control group.
 
Benchworks plans to maximize brand recognition by positioning SUGARDOWN as an adjunct to diet and exercise, beyond the current intended use as a dietary supplement, to better manage blood sugar levels. Benchworks plans to take a three-pronged approach in order to broaden awareness of the potential benefits of SUGARDOWN and increase brand recognition: (1) increase awareness among people who may be at risk of developing diabetes and their caregivers; (2) create a bond with healthcare educators and nutritionists who would recommend SUGARDOWN for their patients; and (3) strengthen SUGARDOWN’s medical profile by continuing to build on new data from additional clinical trial results and new scientific findings. 

Read More

Topics: BTHE

Pressure BioSciences, Inc. (PBIO) Reports Fourth Quarter and Fiscal Year 2013 Financial Results

Posted by Samy Goldfarb

April 2, 2014 at 12:15 PM

Pressure BioSciences, Inc. (PBIO-OTC), a company that develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market, announced financial results for the three-month period and fiscal year ended December 31, 2013, and provided a business update.

Read More

Topics: Pressure BioSciences

ISCO Receives Award for its Metabolic Liver Disease Program

Posted by Samy Goldfarb

December 18, 2013 at 10:49 AM

 

Read More

Topics: ISCO, human induced pluripotent stem cell

ISCO Announces Major Advance in iPS Stem Cell Technology

Posted by Samy Goldfarb

December 9, 2013 at 11:54 AM

International Stem Cell Corporation (ISCO:OTCQB), a biotechnology company developing novel stem cell-based therapies, announced the development of a new method for the derivation of human induced pluripotent stem cells (iPS) that utilizes a novel protein-based reprogramming process. The Company believes that the new method is a safer and more efficient alternative to older iPS reprogramming techniques, and represents a step forward in the ability to use iPS clinically.

Read More

Topics: ISCO, human induced pluripotent stem cell

ISCO: Third Quarter 2013 Financials and Business Update

Posted by Samy Goldfarb

November 13, 2013 at 1:37 PM

International Stem Cell Corp. (ISCO-OTCQB), a biotechnology company developing novel stem cell-based therapies and biomedical products, provided a business update and announced financial results for the three and nine months ended September 30, 2013.

Read More

Topics: ISCO

Authentidate Holding Corp. (ADAT) Second Quarter FY 2012 Update

Posted by Samy Goldfarb

February 29, 2012 at 2:59 PM

Crystal Research continued its coverage of Authentidate Holding Corp. (ADAT-NASDAQ) with the publication of a 16-page Quarterly Update covering the second quarter FY 2012, available here.

Read More

Topics: Crystal Research Associates, New Research, Authentidate, Inscrybe, ExpressMD, telemedicine

Independent Equity Research Report on T3 Motion, Inc. (TTTM)

Posted by Samy Goldfarb

February 15, 2012 at 1:35 PM

Crystal Research has initiated coverage on T3 Moton, Inc. (TTTM-NYSE Amex) with the publication of a 56-page Executive Informational Overview® available here.

Read More

Topics: Crystal Research Associates, T3 Motion, New Research

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic